Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and Implications for Treatment Under the Recent NCEP Writing Group Recommendations
Abstract
The most recent national survey of compliance with the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) guidelines was completed before ATP III and showed significant underachievement of low-density lipoprotein (LDL) cholesterol goals. The NCEP Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II was a national survey conducted in 2003. Of the 4,885 patients, 67% achieved their LDL cholesterol treatment goal, including 89%, 76%, and 57%, respectively, in the 0 or 1 risk factor, > or = 2 risk factors or coronary heart disease (CHD), and CHD risk equivalent categories. The percentage with triglyceride concentrations > or = 200 mg/dl (2.25 mmol/L) in each risk category who achieved their LDL cholesterol and non-high-density lipoprotein cholesterol goals was 64%, 52%, and 27%, respectively. Patients with diabetes (55%) and other CHD risk equivalents (40%) were less likely to have achieved their LDL cholesterol targets than those with CHD (62%). Of the 1,447 patients with cardiovascular disease, 75% could be classified as very high risk according to the new July 2004 NCEP Writing Group recommendations, and 17.8% of those at very high risk had an LDL cholesterol level of <70 mg/dl (<1.81 mmol/L). In conclusion, these results suggest improved lipid management compared with previous surveys. The largest treatment gaps were found for features new to ATP III as of July 2004, including goal achievement for patients with CHD risk equivalents and for non-high-density lipoprotein cholesterol targets. Most of those (75%) with cardiovascular disease in NEPTUNE II would be considered very high risk and candidates for aggressive therapy to reach the new optional treatment goals.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the NEPTUNE II survey, the proportion of individuals with triglyceride levels >=200 mg/dL who had achieved their non-HDL-C goal ranged from 64% with 0 to 1 risk factor to 52% with >=2 risk factors and only 27% with CVD risk equivalents.
“For example, in the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey, the proportion of individuals with triglyceride levels Ն200 mg/dL who had achieved their non-HDL-C goal ranged from 64% with 0 to 1 risk factor to 52% with Ն2 risk factors and only 27% with CVD risk equivalents.223”
From Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association (2011) · cites this paper as [223]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944 · see citing works
Self-citationExpert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011 · see citing works
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902 · see citing works
Self-citationThe Lipid Treatment Assessment Project (L-TAP)
Pearson, T. A., Laurora, I., Chu, H., & Kafonek, S. D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.459 · Cited by 1,012 · see citing works
Self-citationFord, E. S., Mokdad, A. H., Giles, W. H., & Mensah, G. A. (2003) · Circulation · doi:10.1161/01.cir.0000066320.27195.b4 · Cited by 355 · see citing works
Intensive Statin Therapy — A Sea Change in Cardiovascular Prevention
Topol, E. J. (2004) · New England Journal of Medicine · doi:10.1056/nejme048061 · Cited by 197 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871 · see citing works
Self-citationHyperlipidemia as a Risk Factor for Cardiovascular Disease
Nelson, R. H. (2012) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2012.11.003 · Cited by 1,113 · see citing works
Dyslipidemia in type 2 diabetes mellitus
Mooradian, A. D. (2009) · Nature Reviews Endocrinology · doi:10.1038/ncpendmet1066 · Cited by 1,053 · see citing works
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913805 · Cited by 818 · see citing works
Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events
Boekholdt, S. M., Hovingh, G. K., Mora, S., Arsenault, B. J., Amarenco, P., Pedersen, T. R., LaRosa, J. C., Waters, D. D., DeMicco, D. A., Simes, R. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.615 · Cited by 581 · see citing works
Fitzgerald, K. J., Frank-Kamenetsky, M. D., Shulga‐Morskaya, S., Liebow, A., Bettencourt, B. R., Sutherland, J. E., Hutabarat, R. M., Clausen, V. A., Karsten, V., Cehelsky, J. E., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61914-5 · Cited by 574 · see citing works
McKenney, J. M., Koren, M. J., Kereiakes, D. J., Hanotin, C., Ferrand, A.-C., & Stein, E. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.007 · Cited by 507 · see citing works
Self-citationCohen, J. D., Brinton, E. A., Ito, M. K., & Jacobson, T. A. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.03.003 · Cited by 486 · see citing works
Davidson, M. H., Stein, E. A., Bays, H. E., Maki, K. C., Doyle, R. T., Shalwitz, R. A., Ballantyne, C. M., & Ginsberg, H. N. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.018 · Cited by 385 · see citing works
Self-citationSachdeva, A., Cannon, C. P., DEEDWANIA, P. C., LaBresh, K. A., Smith, S. C., Dai, D., Hernandez, A. F., & Fonarow, G. C. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.08.010 · Cited by 329 · see citing works
Self-citationLipid Treatment Assessment Project 2
Waters, D. D., Brotons, C., Chiang, C.-W., Ferrières, J., Foody, J. M., Jukema, J. W., Santos, R. D., Verdejo, J., Messig, M., McPherson, R., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.838466 · Cited by 305 · see citing works
Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., Leon, J. D., Glass, A. D., & Reiss, A. B. (2021) · Metabolites · doi:10.3390/metabo11100690 · Cited by 284 · see citing works
Davidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.07.005 · Cited by 262 · see citing works
Self-citationWei, M. Y., Ito, M. K., Cohen, J. D., Brinton, E. A., & Jacobson, T. A. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.03.001 · Cited by 254 · see citing works
Kühnast, S., van der Hoorn, J. W. A., Pieterman, E. J., van den Hoek, A. M., Sasiela, W. J., Gusarova, V., Peyman, A., Schäfer, H.-L., Schwahn, U., Jukema, J. W., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m051326 · Cited by 204 · see citing works
CYP3A4*22: Promising Newly IdentifiedCYP3A4Variant Allele for Personalizing Pharmacotherapy
Elens, L., van Gelder, T., Hesselink, D. A., Haufroid, V., & van Schaik, R. H. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.187 · Cited by 205 · see citing works
Ballantyne, C. M., Weiss, R., Moccetti, T., Vogt, A., Eber, B., Sosef, F., & Duffield, E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.10.022 · Cited by 196 · see citing works
Self-citationThe importance of non–HDL cholesterol reporting in lipid management
Blaha, M. J., Blumenthal, R. S., Brinton, E. A., & Jacobson, T. A. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.06.013 · Cited by 193 · see citing works
Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering
Pletcher, M. J., Lazar, L., Bibbins-Domingo, K. B., Moran, A., Rodondi, N., Coxson, P. G., Lightwood, J., Williams, L., & Goldman, L. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-4-200902170-00005 · Cited by 187 · see citing works
Selected physiologic compatibilities and incompatibilities between human and porcine organ systems
Ibrahim, Z., Busch, J., Awwad, M., Wagner, R. A., Wells, K. D., & Cooper, D. K. C. (2006) · Xenotransplantation · doi:10.1111/j.1399-3089.2006.00346.x · Cited by 184 · see citing works
Akdim, F., Visser, M. E., Tribble, D. L., Baker, B. F., Stroes, E. S. G., Yu, R. Z., Flaim, J., Su, J. Q., Stein, E. A., & Kastelein, J. J. P. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.01.003 · Cited by 178 · see citing works
Nicholls, S. J., Lincoff, A. M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., Mozaffarian, D., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23055 · Cited by 167 · see citing works
Self-citationContemporary Management of Dyslipidemia in High-Risk Patients: Targets Still Not Met
Yan, A. T.-K., Yan, R. T., Tan, M., Hackam, D. G., Leblanc, K., Kertland, H. R., Tsang, J. L. Y., Jaffer, S., Kates, M. L., Leiter, L. A., et al. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.11.015 · Cited by 158 · see citing works
Diamond, G. A., & Kaul, S. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.083 · Cited by 149 · see citing works
Clinical efficacy and safety of statins in managing cardiovascular risk
Kapur, N. K. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1653 · Cited by 142 · see citing works
Frambach, S. J. C. M., de Haas, R., Smeitink, J. A. M., Rongen, G. A. P. J. M., Rüssel, F. G. M., & Schirris, T. J. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.119.017897 · Cited by 145 · see citing works
Jones, P. H., Nair, R., & Thakker, K. M. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.001800 · Cited by 119 · see citing works
Elens, L., Becker, M. L., Haufroid, V., Albert Hofman, D., Visser, L. E., Uitterlinden, A. G., Stricker, B. H. C., & van Schaik, R. H. N. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834c6edb · Cited by 114 · see citing works
Lai, J., Wu, B., Xuan, T., Liu, Z., & Chen, J.-Z. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-1 · Cited by 112 · see citing works
Miller, M., Ginsberg, H. N., & Schaefer, E. J. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.11.046 · Cited by 102 · see citing works
González‐Juanatey, J. R., Millán, J., Alegría, E., Guijarro, C., Lozano, J. V., & Vitale, G. C. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2010.10.030 · Cited by 99 · see citing works
Doroodchi, H., Abdolrasulnia, M., Foster, J. A., Foster, E., Turakhia, M. P., Skelding, K. A., Sagar, K. B., & Casebeer, L. L. (2008) · BMC Family Practice · doi:10.1186/1471-2296-9-42 · Cited by 98 · see citing works
Managing the underestimated risk of statin-associated myopathy
Rallidis, L. S., Fountoulaki, K., & ANASTASIOU‐NANA, M. I. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.07.048 · Cited by 96 · see citing works
Mariscalco, G., Lorusso, R., Klersy, C., Ferrarese, S., Tozzi, M., Vanoli, D., Domenico, B. V., & Sala, A. (2007) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2007.05.021 · Cited by 97 · see citing works
Treatment With Ezetimibe Plus Low-Dose Atorvastatin Compared With Higher-Dose Atorvastatin Alone
Piorkowski, M., Fischer, S., Stellbaum, C., Jaster, M., Martus, P., Morguet, A. J., Schultheiss, H., & Rauch, U. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.064 · Cited by 93 · see citing works
Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges.
Virani, S. S. (2011) · Europe PMC (PubMed Central) · Cited by 92 · see citing works
Ross, S., D’Mello, M., Anand, S. S., Eikelboom, J., CARDIoGRAMplusC4D Consortium*, Stewart, A. F. R., Samani, N. J., Roberts, R., & Paré, G. (2015) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.114.000952 · Cited by 90 · see citing works
Leiter, L. A., Bays, H. E., Conard, S. E., Bird, S. R., Rubino, J., Hanson, M. E., Tomassini, J. E., & Tershakovec, A. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.076 · Cited by 90 · see citing works
Steinberg, B. A., Bhatt, D. L., Mehta, S. R., Poole-Wilson, P. A., O’Hagan, P., Montalescot, G., Ballantyne, C. M., & Cannon, C. P. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.05.020 · Cited by 90 · see citing works
Self-citationCostet, P., Hoffmann, M. M., Cariou, B., Guyomarch, B., Konrad, T., & Winkler, K. E. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.027 · Cited by 89 · see citing works
Voora, D., Shah, S. H., Reed, C. R., Zhai, J., Crosslin, D. R., Messer, C. J., Salisbury, B. A., & Ginsburg, G. S. (2008) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.108.795013 · Cited by 88 · see citing works
The 'forgotten' bile acid sequestrants: is now a good time to remember?
Bays, H. E., & Goldberg, R. B. (2007) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31815a69fc · Cited by 83 · see citing works
A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations
Ling (2013) · Cardiology Research · doi:10.4021/cr270w · Cited by 85 · see citing works
Reducing Residual Risk for Patients on Statin Therapy: The Potential Role of Combination Therapy
Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.002 · Cited by 81 · see citing works
Self-citationClinical Relevance of Non-HDL Cholesterol in Patients With Diabetes
Peters, A. L. (2008) · Clinical Diabetes · doi:10.2337/diaclin.26.1.3 · Cited by 78 · see citing works
Keevil, J. G., Cullen, M. W., Gangnon, R. E., McBride, P. E., & Stein, J. H. (2007) · Circulation · doi:10.1161/circulationaha.106.645473 · Cited by 76 · see citing works
Davidson, M. H. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.1.145 · Cited by 76 · see citing works
Self-citationKühnast, S., van der Tuin, S. J. L., van der Hoorn, J. W. A., van Klinken, J. B., Simic, B., Pieterman, E. J., Havekes, L. M., Landmesser, U., Lüscher, T. F., van Dijk, K. W., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu319 · Cited by 76 · see citing works
Effectiveness of Combined Statin Plus Omega-3 Fatty Acid Therapy for Mixed Dyslipidemia
Barter, P. J., & Ginsberg, H. N. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.05.056 · Cited by 72 · see citing works
Davidson, M. H., Maki, K. C., Bays, H., Carter, R., & Ballantyne, C. M. (2009) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2009.08.001 · Cited by 71 · see citing works
Self-citationFarnier, M., Averna, M. R., Missault, L. H., Vaverková, H., Viigimaa, M., Massaad, R., Vandormael, K., Johnson‐Levonas, A. O., & Brudi, P. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02022.x · Cited by 71 · see citing works
Karalis, D. G., Victor, B. M., Ahedor, L., & Liu, L. (2012) · Cholesterol · doi:10.1155/2012/861924 · Cited by 68 · see citing works
Merz, C. N. B., Alberts, M. J., Balady, G. J., Ballantyne, C. M., Berra, K. A., Black, H. R., Blumenthal, R. S., Davidson, M. H., Fazio, S. B., Ferdinand, K. C., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192640 · Cited by 64 · see citing works
Self-citationSaposnik, G., Goodman, S. G., Leiter, L. A., Yan, R. T., FITCHETT, D. H., Bayer, N. H., Casanova, A., Langer, A., Yan, A. T.-K., & Guidelines-Oriented Approach to Lipid-Lowering (GOALL) Registries Investigators (2009) · Stroke · doi:10.1161/strokeaha.108.533018 · Cited by 64 · see citing works
Differences between clinical trial efficacy and real-world effectiveness.
Davidson, M. H. (2006) · PubMed · Cited by 57 · see citing works
Self-citationKühnast, S., Fiocco, M. F., van der Hoorn, J. W. A., Princen, H. M. G., & Jukema, J. W. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.089 · Cited by 55 · see citing works
Virani, S. S., Woodard, L., Chitwood, S. S., Landrum, C. R., Urech, T. H., Wang, D., Murawsky, J., Ballantyne, C. M., & Petersen, L. A. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.07.013 · Cited by 56 · see citing works
Self-citationKaras, R. H., Kashyap, M. L., Knopp, R. H., Keller, L. H., Bajorunas, D. R., & Davidson, M. H. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200808020-00001 · Cited by 56 · see citing works
Self-citationBays, H. E., McKenney, J., Maki, K. C., Doyle, R. T., Carter, R. N., & Stein, E. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0397 · Cited by 54 · see citing works
Self-citationGoodman, S. G., Langer, A., Bastien, N. R., McPherson, R., Francis, G. A., Genest, J. J., & Leiter, L. A. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)70454-2 · Cited by 54 · see citing works
Marais, A. D., Kim, J. B., Wasserman, S. M., & Lambert, G. C. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.004 · Cited by 53 · see citing works
Molecular pathways and agents for lowering LDL-cholesterol in addition to statins
Costet, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.006 · Cited by 53 · see citing works
Merz, C. N. B., Alberts, M. J., Balady, G. J., Ballantyne, C. M., Berra, K. A., Black, H. R., Blumenthal, R. S., Davidson, M. H., Fazio, S. B., Ferdinand, K. C., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.05.019 · Cited by 53 · see citing works
Self-citationCritical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals
Saitō, Y. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5551 · Cited by 53 · see citing works
A Review of Lipid Management in Primary and Secondary Prevention
Dembowski, E., & Davidson, M. H. (2009) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0b013e318192754e · Cited by 52 · see citing works
Self-citationClinical features of familial Mediterranean fever: an Italian overview.
Manna, R., Cerquaglia, C., Curigliano, V., Fonnesu, C., Giovinale, M., Verrecchia, E., Montalto, M., Socio, G. D., Soriano, A., Regina, M. L., et al. (2009) · PubMed · Cited by 51 · see citing works
Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects
Davidson, M. H., Bays, H. E., Stein, E., Maki, K. C., Shalwitz, R. A., & Doyle, R. (2006) · Clinical Cardiology · doi:10.1002/clc.4960290609 · Cited by 51 · see citing works
Self-citationGonzález‐Juanatey, J. R., Alegría-Ezquerra, E., Aznar, J., Bertoméu, V., Franch‐Nadal, J., & Palma-Gámiz, J. L. (2006) · Revista Española de Cardiología · doi:10.1157/13091884 · Cited by 51 · see citing works
Atherosclerosis: Immune and Inflammatory Aspects
Reiss, A. B., & Glass, A. D. (2006) · Journal of Investigative Medicine · doi:10.2310/6650.2006.05051 · Cited by 50 · see citing works
Ezetimibe Ameliorates Metabolic Disorders and Microalbuminuria in Patients with Hypercholesterolemia
Yagi, S., Akaike, M., Aihara, K., Iwase, T., Ishikawa, K., Yoshida, S., Sumitomo-Ueda, Y., Kusunose, K., Niki, T., Yamaguchi, K., et al. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.2378 · Cited by 47 · see citing works
Virani, S. S., Woodard, L., Landrum, C. R., Pietz, K., Wang, D., Ballantyne, C. M., & Petersen, L. A. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.03.023 · Cited by 46 · see citing works
Self-citationBermingham, M., Hayden, J. C., Dawkins, I. R., Miwa, S., Gibson, D., McDonald, K., & Ledwidge, M. T. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.07.007 · Cited by 46 · see citing works
Li, N., Li, Q., Tian, X.-Q., Qian, H.-Y., & Yang, Y.-J. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0077-0 · Cited by 45 · see citing works
Apolipoprotein B synthesis inhibition: results from clinical trials
Visser, M. E., Kastelein, J. J. P., & Stroes, E. S. G. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833af4c1 · Cited by 44 · see citing works
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction
Robinson, J. G., & Davidson, M. H. (2006) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.4.4.461 · Cited by 44 · see citing works
Self-citationAchieving Optimal Lipid Goals in Patients With Coronary Artery Disease
Karalis, D. G., Subramanya, R. D., Hessen, S. E., Liu, L., & Victor, M. F. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.11.006 · Cited by 43 · see citing works
Squalene synthase inhibition: A novel target for the management of dyslipidemia
Davidson, M. H. (2007) · Current Atherosclerosis Reports · doi:10.1007/bf02693932 · Cited by 43 · see citing works
Self-citationJacobson, T. A. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0128 · Cited by 42 · see citing works
Lipid-lowering therapy: who can benefit
Lewis, S. J. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s23113 · Cited by 43 · see citing works
Nag, S. S., Daniel, G. W., Bullano, M. F., Kamal‐Bahl, S. J., Sajjan, S. G., Hu, H. X., & Alexander, C. M. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.8.652 · Cited by 41 · see citing works
Ansell, B. J., Fonarow, G. C., Maki, K. C., Dicklin, M. R., Bell, M., & Davidson, M. H. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.05.013 · Cited by 41 · see citing works
Self-citationMitchell, S., Roso, S., Samuel, M., & Pladevall-Vila, M. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0241-3 · Cited by 40 · see citing works
Perspectives on low-density-lipoprotein cholesterol goal achievement
Catapano, A. L. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802631438 · Cited by 40 · see citing works
Rubenfire, M., Brook, R. D., & Rosenson, R. S. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.03.024 · Cited by 40 · see citing works
Gitt, A. K., Jünger, C., Smolka, W., & Bestehorn, K. P. (2010) · Clinical Research in Cardiology · doi:10.1007/s00392-010-0177-z · Cited by 40 · see citing works
Insull, W., Ghali, J. K., Hassman, D. R., Yčas, J. W., Gandhi, S. K., & Miller, E. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.5.543 · Cited by 40 · see citing works
Santos, R. D., Waters, D. D., Tarasenko, L., Messig, M., Jukema, J. W., Chiang, C.-W., Ferrieres, J., & Foody, J. M. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.06.052 · Cited by 39 · see citing works
Melloni, C., Shah, B. R., Ou, F., Roe, M. T., Smith, S. C., Pollack, C. V., Ohman, M. E., Gibler, W. B., Peterson, E. D., & Alexander, K. P. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.09.008 · Cited by 39 · see citing works
Bhan, V., Yan, R. T., Leiter, L. A., FITCHETT, D. H., Langer, A., Lonn, E., Tan, M., Silagy, S., Goodman, S. G., & Yan, A. T.-K. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.06.055 · Cited by 38 · see citing works
Girona, J., Ibarretxe, D., Plana, N., Guaita‐Esteruelas, S., Amigó, N., Heras, M., & Masana, L. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0428-z · Cited by 38 · see citing works
Ballantyne, C. M., Davidson, M. H., McKenney, J. M., Keller, L. H., Bajorunas, D. R., & Karas, R. H. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.02.004 · Cited by 38 · see citing works
Self-citationNovel nonstatin strategies to lower low-density lipoprotein cholesterol
Davidson, M. H. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0011-0 · Cited by 38 · see citing works
Self-citationEthnic differences in achievement of cholesterol treatment goals
Clark, L. T., Maki, K. C., Galant, R., Maron, D. J., Pearson, T. A., & Davidson, M. H. (2006) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2006.00349.x · Cited by 38 · see citing works
Self-citationFish oil in the treatment of dyslipidemia
Goldberg, R. B., & Sabharwal, A. K. (2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282f76728 · Cited by 37 · see citing works
González‐Juanatey, J. R., Millán, J., Alegría, E., Guijarro, C., Lozano, J. V., & Vitale, G. C. (2011) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2010.10.030 · Cited by 35 · see citing works
Conard, S. E., Bays, H. E., Leiter, L. A., Bird, S., Lin, J., Hanson, M. E., Shah, A. K., & Tershakovec, A. M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01152.x · Cited by 35 · see citing works
Gui, Y., Yao, S., Yan, H., Hu, L., Yu, C., Gao, F., Xi, C., Li, H., Ye, Y., & Wang, Y. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw183 · Cited by 35 · see citing works
Kurobe, H., Aihara, K., Higashida, M., Hirata, Y., Nishiya, M., Matsuoka, Y., Kanbara, T., Nakayama, T., Kinoshita, H., Sugano, M., et al. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.9548 · Cited by 35 · see citing works
Other Therapies for Reducing Low-Density Lipoprotein Cholesterol: Medications in Development
Stein, E. A. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.11.011 · Cited by 34 · see citing works
Attainment of low-density lipoprotein cholesterol goals in coronary artery disease
Kauffman, A. B., Olson, K. L., Youngblood, M., Zadvorny, E. B., Delate, T., & Merenich, J. A. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.03.002 · Cited by 34 · see citing works
- Authors
- Davidson, M. H., Maki, K. C., Pearson, T. A., Pasternak, R. C., Deedwania, P. C., McKenney, J. M., Fonarow, G. C., Maron, D. J., Ansell, B. J., Clark, L. T., & Ballantyne, C. M.
- Affiliations
- University of Rochester Medicine (US)
- Massachusetts General Hospital (US)
- National Clinical Research (US)
- University of California, Los Angeles (US)
- Vanderbilt University (US)
- SUNY Downstate Health Sciences University (US)
- Baylor College of Medicine (US)
- Corresponding author
- Davidson, Michael H.
- ORCID
- Venue
- The American Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 2005-08
- Volume
- 96
- Issue
- 4
- Pages
- 556-563
- ISSN
- 0002-9149 (ISSN-L)
- OpenAlex
- W1969054950
- Cited by
- 270
- References
- 6
- Citations by year
- 2026: 1 · 2024: 1 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 5 · 2018: 3 · 2017: 5 · 2016: 4 · 2015: 12 · 2014: 15 · 2013: 16 · 2012: 19
- FWCI
- 28.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- National Cholesterol Education Program, Adult Treatment Panel III, non-HDL cholesterol, cardiovascular risk stratification, very high-risk patients, coronary artery disease, diabetes mellitus, treatment gap, lipid control, aggressive lipid-lowering therapy
- MeSH terms
- Anticholesteremic Agents, Cholesterol, Coronary Artery Disease, Female, Follow-Up Studies, Health Surveys, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Medical Laboratory Science, Hypertriglyceridemia, Program Evaluation, Treatment Outcome, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
